Capricor Therapeutics Inc (CAPR) Actualités

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel...

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data...

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company...

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment PR...

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities